Literature DB >> 11032864

Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1.

R P van Rij1, H Blaak, J A Visser, M Brouwer, R Rientsma, S Broersen, A M de Roda Husman, H Schuitemaker.   

Abstract

We demonstrated previously that CD45RA(+) CD4(+) T cells are infected primarily by syncytium-inducing (SI) HIV-1 variants, whereas CD45RO(+) CD4(+) T cells harbor both non-SI (NSI) and SI HIV-1 variants. Here, we studied evolution of tropism for CD45RA(+) and CD45RO(+) CD4(+) cells, coreceptor usage, and molecular phylogeny of coexisting NSI and SI HIV-1 clones that were isolated from four patients in the period spanning SI conversion. NSI variants were CCR5-restricted and could be isolated throughout infection from CD45RO(+) CD4(+) cells. SI variants seemed to evolve in CD45RO(+) CD4(+) cells, but, in time, SI HIV-1 infection of CD45RA(+) CD4(+) cells equaled infection of CD45RO(+) CD4(+) cells. In parallel with this shift, SI HIV-1 variants first used both coreceptors CCR5 and CXCR4, but eventually lost the ability to use CCR5. Phylogenetically, NSI and SI HIV-1 populations diverged over time. We observed a differential expression of HIV-1 coreceptors within CD45RA(+) and CD45RO(+) cells, which allowed us to isolate virus from purified CCR5(+) CXCR4(-) and CCR5(-) CXCR4(+) CD4(+) cells. The CCR5(+) subset was exclusively infected by CCR5-dependent HIV-1 clones, whereas SI clones were preferentially isolated from the CXCR4(+) subset. The differential expression of HIV-1 coreceptors provides distinct cellular niches for NSI and SI HIV-1, contributing to their coexistence and independent evolutionary pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032864      PMCID: PMC314337          DOI: 10.1172/JCI7953

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  67 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.

Authors:  A M de Roda Husman; R P van Rij; H Blaak; S Broersen; H Schuitemaker
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).

Authors:  M D Hazenberg; J W Stuart; S A Otto; J C Borleffs; C A Boucher; R J de Boer; F Miedema; D Hamann
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

6.  HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Authors:  M Koot; A H Vos; R P Keet; R E de Goede; M W Dercksen; F G Terpstra; R A Coutinho; F Miedema; M Tersmette
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

7.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  31 in total

1.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals.

Authors:  Alan R Templeton; Rebecca A Reichert; Anton E Weisstein; Xiao-Fang Yu; Richard B Markham
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

4.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

6.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.

Authors:  William L Ince; Patrick R Harrington; Gretja L Schnell; Milloni Patel-Chhabra; Christina L Burch; Prema Menezes; Richard W Price; Joseph J Eron; Ronald I Swanstrom
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

10.  Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.

Authors:  Edwin J Heeregrave; Mark J Geels; Jason M Brenchley; Elly Baan; David R Ambrozak; Renee M van der Sluis; Rune Bennemeer; Daniel C Douek; Jaap Goudsmit; Georgios Pollakis; Richard A Koup; William A Paxton
Journal:  Virology       Date:  2009-08-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.